Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Cognitive heterogeneity in probable Alzheimer disease: Clinical and neuropathologic features.

Qiu Y, Jacobs DM, Messer K, Salmon DP, Feldman HH.

Neurology. 2019 Aug 20;93(8):e778-e790. doi: 10.1212/WNL.0000000000007967. Epub 2019 Jul 18.

PMID:
31320469
2.

The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study.

Chertkow H, Borrie M, Whitehead V, Black SE, Feldman HH, Gauthier S, Hogan DB, Masellis M, McGilton K, Rockwood K, Tierney MC, Andrew M, Hsiung GR, Camicioli R, Smith EE, Fogarty J, Lindsay J, Best S, Evans A, Das S, Mohaddes Z, Pilon R, Poirier J, Phillips NA, MacNamara E, Dixon RA, Duchesne S, MacKenzie I, Rylett RJ.

Can J Neurol Sci. 2019 Jul 16:1-13. doi: 10.1017/cjn.2019.27. [Epub ahead of print]

PMID:
31309917
3.

Safety and Efficacy of Edonerpic Maleate for Patients With Mild to Moderate Alzheimer Disease: A Phase 2 Randomized Clinical Trial.

Schneider LS, Thomas RG, Hendrix S, Rissman RA, Brewer JB, Salmon DP, Oltersdorf T, Okuda T, Feldman HH; Alzheimer’s Disease Cooperative Study TCAD Study Group.

JAMA Neurol. 2019 Jul 8. doi: 10.1001/jamaneurol.2019.1868. [Epub ahead of print]

4.

Delayed daily activity and reduced NREM slow-wave power in the APPswe/PS1dE9 mouse model of Alzheimer's disease.

Kent BA, Michalik M, Marchant EG, Yau KW, Feldman HH, Mistlberger RE, Nygaard HB.

Neurobiol Aging. 2019 Jun;78:74-86. doi: 10.1016/j.neurobiolaging.2019.01.010. Epub 2019 Feb 14.

PMID:
30884411
5.

A randomized clinical trial to evaluate home-based assessment of people over 75 years old.

Sano M, Zhu CW, Kaye J, Mundt JC, Hayes TL, Ferris S, Thomas RG, Sun CK, Jiang Y, Donohue MC, Schneider LS, Egelko S, Aisen PS, Feldman HH; Alzheimer Disease Cooperative Study Investigators.

Alzheimers Dement. 2019 May;15(5):615-624. doi: 10.1016/j.jalz.2019.01.007. Epub 2019 Mar 11.

PMID:
30872114
6.

Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication.

Huisa BN, Thomas RG, Jin S, Oltersdorf T, Taylor C, Feldman HH.

J Alzheimers Dis. 2019;67(2):707-713. doi: 10.3233/JAD-180684.

PMID:
30636733
7.

Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer's disease.

Broce IJ, Tan CH, Fan CC, Jansen I, Savage JE, Witoelar A, Wen N, Hess CP, Dillon WP, Glastonbury CM, Glymour M, Yokoyama JS, Elahi FM, Rabinovici GD, Miller BL, Mormino EC, Sperling RA, Bennett DA, McEvoy LK, Brewer JB, Feldman HH, Hyman BT, Pericak-Vance M, Haines JL, Farrer LA, Mayeux R, Schellenberg GD, Yaffe K, Sugrue LP, Dale AM, Posthuma D, Andreassen OA, Karch CM, Desikan RS.

Acta Neuropathol. 2019 Feb;137(2):209-226. doi: 10.1007/s00401-018-1928-6. Epub 2018 Nov 9.

8.

Therapeutic trial design for frontotemporal dementia and related disorders.

Desmarais P, Rohrer JD, Nguyen QD, Herrmann N, Stuss DT, Lang AE, Boxer AL, Dickerson BC, Rosen H, van Swieten JC, Meeter LH, Borroni B, Tartaglia MC, Feldman HH, Black SE, Masellis M.

J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):412-423. doi: 10.1136/jnnp-2018-318603. Epub 2018 Oct 25. Review.

PMID:
30361298
9.

Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial.

Sano M, Egelko S, Zhu CW, Li C, Donohue MC, Ferris S, Kaye J, Mundt JC, Sun CK, Aisen PS, Feldman HH.

Alzheimers Dement. 2018 Nov;14(11):1397-1405. doi: 10.1016/j.jalz.2018.05.016. Epub 2018 Oct 5.

PMID:
30297140
10.

Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY).

Finger E, Berry S, Cummings J, Coleman K, Hsiung R, Feldman HH, Boxer A.

Alzheimers Res Ther. 2018 Sep 27;10(1):102. doi: 10.1186/s13195-018-0427-2.

11.

Gray matter changes in asymptomatic C9orf72 and GRN mutation carriers.

Popuri K, Dowds E, Beg MF, Balachandar R, Bhalla M, Jacova C, Buller A, Slack P, Sengdy P, Rademakers R, Wittenberg D, Feldman HH, Mackenzie IR, Hsiung GR.

Neuroimage Clin. 2018 Feb 17;18:591-598. doi: 10.1016/j.nicl.2018.02.017. eCollection 2018.

12.

16-Year Survival of the Canadian Collaborative Cohort of Related Dementias.

Lichtenstein ML, Fallah N, Mudge B, Hsiung GR, Foti D, Beattie BL, Feldman HH.

Can J Neurol Sci. 2018 Jul;45(4):367-374. doi: 10.1017/cjn.2018.6. Epub 2018 May 7.

PMID:
29730995
13.

Neurobehavioral characterization of adult-onset Alexander disease: A family study.

Lichtenstein ML, Dwosh E, Roy Chowdhury A, Farrer MJ, McKenzie MB, Guella I, Evans DM, Nygaard HB, Shewchuk JR, Hayden S, Barton JJS, Feldman HH.

Neurol Clin Pract. 2017 Oct;7(5):425-429. doi: 10.1212/CPJ.0000000000000356. No abstract available.

14.

The 2002 NIMH Provisional Diagnostic Criteria for Depression of Alzheimer's Disease (PDC-dAD): Gauging their Validity over a Decade Later.

Sepehry AA, Lee PE, Hsiung GR, Beattie BL, Feldman HH, Jacova C.

J Alzheimers Dis. 2017;58(2):449-462. doi: 10.3233/JAD-161061. Review.

PMID:
28453472
15.

The Canadian dementia challenge: Ensuring optimal care and services for those at risk or with dementia throughout the country.

Feldman HH, Estabrooks CA.

Can J Public Health. 2017 Apr 20;108(1):e95-e97. doi: 10.17269/cjph.108.5852.

PMID:
28425906
16.

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.

Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ, Schelter BO, Davis CS, Staff RT, Bracoud L, Shamsi K, Storey JM, Harrington CR, Wischik CM.

Lancet. 2016 Dec 10;388(10062):2873-2884. doi: 10.1016/S0140-6736(16)31275-2. Epub 2016 Nov 16.

17.

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers.

Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knopman DS, Petersen RC, Scheltens P, Sperling RA, Dubois B.

Neurology. 2016 Aug 2;87(5):539-47. doi: 10.1212/WNL.0000000000002923. Epub 2016 Jul 1. Review.

18.

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.

Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, Epelbaum S, Frisoni GB, Gauthier S, Genthon R, Gouw AA, Habert MO, Holtzman DM, Kivipelto M, Lista S, Molinuevo JL, O'Bryant SE, Rabinovici GD, Rowe C, Salloway S, Schneider LS, Sperling R, Teichmann M, Carrillo MC, Cummings J, Jack CR Jr; Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on “The Preclinical State of AD”; July 23, 2015; Washington DC, USA.

Alzheimers Dement. 2016 Mar;12(3):292-323. doi: 10.1016/j.jalz.2016.02.002. Review.

19.

Periventricular hyperintensities are associated with elevated cerebral amyloid.

Marnane M, Al-Jawadi OO, Mortazavi S, Pogorzelec KJ, Wang BW, Feldman HH, Hsiung GY; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2016 Feb 9;86(6):535-43. doi: 10.1212/WNL.0000000000002352. Epub 2016 Jan 8.

20.

Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial.

Coric V, Salloway S, van Dyck CH, Dubois B, Andreasen N, Brody M, Curtis C, Soininen H, Thein S, Shiovitz T, Pilcher G, Ferris S, Colby S, Kerselaers W, Dockens R, Soares H, Kaplita S, Luo F, Pachai C, Bracoud L, Mintun M, Grill JD, Marek K, Seibyl J, Cedarbaum JM, Albright C, Feldman HH, Berman RM.

JAMA Neurol. 2015 Nov;72(11):1324-33. doi: 10.1001/jamaneurol.2015.0607.

21.

Early neuropsychological characteristics of progranulin mutation carriers.

Hallam BJ, Jacova C, Hsiung GY, Wittenberg D, Sengdy P, Bouchard-Kerr P, Slack P, Rademakers R, Baker M, Chow TW, Levine B, Feldman HH, Mackenzie IR.

J Int Neuropsychol Soc. 2014 Aug;20(7):694-703. doi: 10.1017/S1355617714000551. Epub 2014 Jul 4.

PMID:
24993774
22.

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL.

Lancet Neurol. 2014 Jun;13(6):614-29. doi: 10.1016/S1474-4422(14)70090-0. Erratum in: Lancet Neurol. 2014 Aug;13(8):757.

PMID:
24849862
23.

Alzheimer's disease research and development: a call for a new research roadmap.

Feldman HH, Haas M, Gandy S, Schoepp DD, Cross AJ, Mayeux R, Sperling RA, Fillit H, van de Hoef DL, Dougal S, Nye JS; One Mind for Research and the New York Academy of Sciences.

Ann N Y Acad Sci. 2014 Apr;1313:1-16. doi: 10.1111/nyas.12424.

PMID:
24754377
24.

Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia.

Chertkow H, Feldman HH, Jacova C, Massoud F.

Alzheimers Res Ther. 2013 Jul 8;5(Suppl 1):S2. doi: 10.1186/alzrt198. Epub 2013 Jul 8.

25.

Evaluation of late-onset Alzheimer disease genetic susceptibility risks in a Canadian population.

Omoumi A, Fok A, Greenwood T, Sadovnick AD, Feldman HH, Hsiung GY.

Neurobiol Aging. 2014 Apr;35(4):936.e5-12. doi: 10.1016/j.neurobiolaging.2013.09.025. Epub 2013 Oct 28.

PMID:
24176626
26.

Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers.

Jacova C, Hsiung GY, Tawankanjanachot I, Dinelle K, McCormick S, Gonzalez M, Lee H, Sengdy P, Bouchard-Kerr P, Baker M, Rademakers R, Sossi V, Stoessl AJ, Feldman HH, Mackenzie IR.

Neurology. 2013 Oct 8;81(15):1322-31. doi: 10.1212/WNL.0b013e3182a8237e. Epub 2013 Sep 4.

27.

GRN-Related Frontotemporal Dementia.

Hsiung GYR, Feldman HH.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2007 Sep 7 [updated 2013 Mar 14].

28.

Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease.

Carrillo MC, Brashear HR, Logovinsky V, Ryan JM, Feldman HH, Siemers ER, Abushakra S, Hartley DM, Petersen RC, Khachaturian AS, Sperling RA.

Alzheimers Dement. 2013 Mar;9(2):123-131.e1. doi: 10.1016/j.jalz.2012.12.004. Epub 2013 Feb 12. Review.

PMID:
23411394
29.

A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease.

Peters KR, Lynn Beattie B, Feldman HH, Illes J.

Prog Neurobiol. 2013 Nov;110:114-23. doi: 10.1016/j.pneurobio.2012.12.001. Epub 2013 Jan 21. Review.

PMID:
23348495
30.

Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.

Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, Pilcher G, Colby S, Rollin L, Dockens R, Pachai C, Portelius E, Andreasson U, Blennow K, Soares H, Albright C, Feldman HH, Berman RM.

Arch Neurol. 2012 Nov;69(11):1430-40.

PMID:
22892585
31.

Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p.

Hsiung GY, DeJesus-Hernandez M, Feldman HH, Sengdy P, Bouchard-Kerr P, Dwosh E, Butler R, Leung B, Fok A, Rutherford NJ, Baker M, Rademakers R, Mackenzie IR.

Brain. 2012 Mar;135(Pt 3):709-22. doi: 10.1093/brain/awr354. Epub 2012 Feb 17.

32.

Synaptic dysfunction in progranulin-deficient mice.

Petkau TL, Neal SJ, Milnerwood A, Mew A, Hill AM, Orban P, Gregg J, Lu G, Feldman HH, Mackenzie IR, Raymond LA, Leavitt BR.

Neurobiol Dis. 2012 Feb;45(2):711-22. doi: 10.1016/j.nbd.2011.10.016. Epub 2011 Oct 25.

PMID:
22062772
33.

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.

Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ.

Alzheimers Dement. 2011 Jul;7(4):367-85. doi: 10.1016/j.jalz.2011.05.2351. Review.

34.

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH.

Alzheimers Dement. 2011 May;7(3):270-9. doi: 10.1016/j.jalz.2011.03.008. Epub 2011 Apr 21.

35.

Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration.

Chen-Plotkin AS, Martinez-Lage M, Sleiman PM, Hu W, Greene R, Wood EM, Bing S, Grossman M, Schellenberg GD, Hatanpaa KJ, Weiner MF, White CL 3rd, Brooks WS, Halliday GM, Kril JJ, Gearing M, Beach TG, Graff-Radford NR, Dickson DW, Rademakers R, Boeve BF, Pickering-Brown SM, Snowden J, van Swieten JC, Heutink P, Seelaar H, Murrell JR, Ghetti B, Spina S, Grafman J, Kaye JA, Woltjer RL, Mesulam M, Bigio E, Lladó A, Miller BL, Alzualde A, Moreno F, Rohrer JD, Mackenzie IR, Feldman HH, Hamilton RL, Cruts M, Engelborghs S, De Deyn PP, Van Broeckhoven C, Bird TD, Cairns NJ, Goate A, Frosch MP, Riederer PF, Bogdanovic N, Lee VM, Trojanowski JQ, Van Deerlin VM.

Arch Neurol. 2011 Apr;68(4):488-97. doi: 10.1001/archneurol.2011.53.

36.

Report of the task force on designing clinical trials in early (predementia) AD.

Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, Potter WZ, Thomas RG, Salmon D, Donohue M, Bednar MM, Touchon J, Vellas B.

Neurology. 2011 Jan 18;76(3):280-6. doi: 10.1212/WNL.0b013e318207b1b9. Epub 2010 Dec 22.

37.

Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance.

Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR Jr, Feldman HH, Bokde AL, Alexander GE, Scheltens P, Vellas B, Dubois B, Weiner M, Hampel H; North American Alzheimer's Disease Neuroimaging Initiative (ADNI).

Neurobiol Aging. 2012 Jul;33(7):1203-14. doi: 10.1016/j.neurobiolaging.2010.10.019. Epub 2010 Dec 14.

38.

Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin.

Hu F, Padukkavidana T, Vægter CB, Brady OA, Zheng Y, Mackenzie IR, Feldman HH, Nykjaer A, Strittmatter SM.

Neuron. 2010 Nov 18;68(4):654-67. doi: 10.1016/j.neuron.2010.09.034.

39.

rs5848 polymorphism and serum progranulin level.

Hsiung GY, Fok A, Feldman HH, Rademakers R, Mackenzie IR.

J Neurol Sci. 2011 Jan 15;300(1-2):28-32. doi: 10.1016/j.jns.2010.10.009. Epub 2010 Nov 2.

40.

Revising the definition of Alzheimer's disease: a new lexicon.

Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P.

Lancet Neurol. 2010 Nov;9(11):1118-27. doi: 10.1016/S1474-4422(10)70223-4. Epub 2010 Oct 9.

PMID:
20934914
41.

Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy.

Olazarán J, Reisberg B, Clare L, Cruz I, Peña-Casanova J, Del Ser T, Woods B, Beck C, Auer S, Lai C, Spector A, Fazio S, Bond J, Kivipelto M, Brodaty H, Rojo JM, Collins H, Teri L, Mittelman M, Orrell M, Feldman HH, Muñiz R.

Dement Geriatr Cogn Disord. 2010;30(2):161-78. doi: 10.1159/000316119. Epub 2010 Sep 10. Review.

42.

Progranulin expression in the developing and adult murine brain.

Petkau TL, Neal SJ, Orban PC, MacDonald JL, Hill AM, Lu G, Feldman HH, Mackenzie IR, Leavitt BR.

J Comp Neurol. 2010 Oct 1;518(19):3931-47. doi: 10.1002/cne.22430.

PMID:
20737593
43.

A novel PS1 gene mutation in a large Aboriginal kindred.

Butler R, Beattie BL, Thong UP, Dwosh E, Guimond C, Feldman HH, Hsiung GY, Rogaeva E, St George-Hyslop P, Sadovnick AD.

Can J Neurol Sci. 2010 May;37(3):359-64.

PMID:
20481270
44.

Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.

Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, Wu X, Gentile KA, Huang SP, Emison E, Delmonte T, D'Souza BB, Zimbroff DL, Grebb JA, Goddard AW, Stock EG.

Depress Anxiety. 2010 May;27(5):417-25. doi: 10.1002/da.20695.

PMID:
20455246
45.

Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.

Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A; LEADe Investigators.

Neurology. 2010 Mar 23;74(12):956-64. doi: 10.1212/WNL.0b013e3181d6476a. Epub 2010 Mar 3.

PMID:
20200346
46.

Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions.

Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-Plotkin A, Wang LS, Graff-Radford NR, Dickson DW, Rademakers R, Boeve BF, Grossman M, Arnold SE, Mann DM, Pickering-Brown SM, Seelaar H, Heutink P, van Swieten JC, Murrell JR, Ghetti B, Spina S, Grafman J, Hodges J, Spillantini MG, Gilman S, Lieberman AP, Kaye JA, Woltjer RL, Bigio EH, Mesulam M, Al-Sarraj S, Troakes C, Rosenberg RN, White CL 3rd, Ferrer I, Lladó A, Neumann M, Kretzschmar HA, Hulette CM, Welsh-Bohmer KA, Miller BL, Alzualde A, Lopez de Munain A, McKee AC, Gearing M, Levey AI, Lah JJ, Hardy J, Rohrer JD, Lashley T, Mackenzie IR, Feldman HH, Hamilton RL, Dekosky ST, van der Zee J, Kumar-Singh S, Van Broeckhoven C, Mayeux R, Vonsattel JP, Troncoso JC, Kril JJ, Kwok JB, Halliday GM, Bird TD, Ince PG, Shaw PJ, Cairns NJ, Morris JC, McLean CA, DeCarli C, Ellis WG, Freeman SH, Frosch MP, Growdon JH, Perl DP, Sano M, Bennett DA, Schneider JA, Beach TG, Reiman EM, Woodruff BK, Cummings J, Vinters HV, Miller CA, Chui HC, Alafuzoff I, Hartikainen P, Seilhean D, Galasko D, Masliah E, Cotman CW, Tuñón MT, Martínez MC, Munoz DG, Carroll SL, Marson D, Riederer PF, Bogdanovic N, Schellenberg GD, Hakonarson H, Trojanowski JQ, Lee VM.

Nat Genet. 2010 Mar;42(3):234-9. doi: 10.1038/ng.536. Epub 2010 Feb 14.

47.

An exploration of cognitive subgroups in Alzheimer's disease.

Davidson JE, Irizarry MC, Bray BC, Wetten S, Galwey N, Gibson R, Borrie M, Delisle R, Feldman HH, Hsiung GY, Fornazzari L, Gauthier S, Guzman D, Loy-English I, Keren R, Kertesz A, George-Hyslop PS, Wherrett J, Monsch AU.

J Int Neuropsychol Soc. 2010 Mar;16(2):233-43. doi: 10.1017/S1355617709991160. Epub 2009 Dec 4.

48.

Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease.

Wilkinson D, Schindler R, Schwam E, Waldemar G, Jones RW, Gauthier S, Lopez OL, Cummings J, Xu Y, Feldman HH.

Dement Geriatr Cogn Disord. 2009;28(3):244-51. doi: 10.1159/000241877. Epub 2009 Sep 25.

49.

Assessing the validity of deriving clinical dementia rating (CDR) global scores from independently-obtained functional rating scale (FRS) scores in vascular dementia with and without Alzheimer's disease.

Lanctôt KL, Hsiung GY, Feldman HH, Masoud ST, Sham L, Herrmann N.

Int J Geriatr Psychiatry. 2009 Oct;24(10):1174-6. doi: 10.1002/gps.2273. No abstract available.

PMID:
19768698
50.

Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach.

Ferris S, Lane R, Sfikas N, Winblad B, Farlow M, Feldman HH.

Gend Med. 2009 Jul;6(2):345-55. doi: 10.1016/j.genm.2009.06.004.

PMID:
19682661

Supplemental Content

Loading ...
Support Center